Melatonin inhibits the proliferation of breast cancer cells induced by bisphenol A via targeting estrogen receptor‐related pathways

Wang, Tianjiao; Liu, Bowen; Guan, Yanan; Gong, Miaomiao; Zhang, Weiying; Pan, Jinjin; Liu, Yanan; Liang, Rui; Yuan, Yuhui; Ye, Lihong

doi:10.1111/1759-7714.12587

Cited by 35 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This creates an increasing need for safe and effective medication and modalities to prevent and treat breast cancer. MLT, a hormone synthesized and released mainly by the pineal gland, is a well‐known, safe pharmaceutical compound with a remarkable anticancer potential …”

Section: Discussionmentioning

confidence: 99%

Ameliorative effects of melatonin against solid Ehrlich carcinoma progression in female mice

Amin

El-Missiry

Othman

et al. 2019

Journal of Pineal Research

View full text Add to dashboard Cite

The current work estimated the antitumour efficacy of melatonin (MLT) on the growth of Ehrlich ascites carcinoma cells inoculated intramuscularly into the hind limbs of female BALB/c mice and to compare its effects with those of adriamycin (ADR). After solid tumours developed, the animals were divided into the three following groups: the tumour‐bearing control, MLT‐treated (20 mg/kg body weight) and ADR‐treated (10 mg/kg body weight) groups. The results showed a significant reduction in the tumour masses of the treated animals in comparison with those of the control group. There were a significant decrease in the malondialdehyde level and a significant elevation of the glutathione concentration and the superoxide dismutase and catalase activities in the MLT and ADR groups. The current study indicated the increased expression levels of P53, caspase‐3 and caspase‐9 and the decreased expression levels of the rRNA and Bcl2. The MLT and ADR treatments resulted in histological changes, such as a marked degenerative area, the necrosis of neoplastic cells, the appearance of different forms of apoptotic cells and giant cells with condensed chromatin, and a deeply eosinophilic cytoplasm. The MLT and ADR treatments also significantly decreased the Ki‐67 protein and vascular endothelial growth factor (VEGF) expression levels in the tumour masses. In conclusion, similar to ADR‐treated tumour‐bearing mice, MLT suppressed the growth and proliferation of tumour by inducing apoptosis and by inhibiting tumour vascularization. The current data recommend MLT as a safe natural chemotherapeutic adjuvant to overcome cancer progression after a clinical trial validates these results.

show abstract

Section: Discussionmentioning

confidence: 99%

Ameliorative effects of melatonin against solid Ehrlich carcinoma progression in female mice

Amin

El-Missiry

Othman

et al. 2019

Journal of Pineal Research

View full text Add to dashboard Cite

show abstract

“…Some genes influenced by estrogen may also be influenced by other hormones, cytokines, or chemicals. Activation of ERα results in the increased phosphorylation of ERK [20,26]. In this study, BPA application increased p-ERK1/2 expression, but 4HR did not (Figure 3).…”

Section: Discussionmentioning

confidence: 44%

4-Hexylresorcinol Exhibits Different Characteristics to Estrogen

Kang

Seok

et al. 2020

Applied Sciences

View full text Add to dashboard Cite

4-Hexylresorcinol (4HR) has been used as a food additive and antiseptic. The aim of this study was to evaluate whether the application of 4HR in breast cancer cells and ovariectomized rats showed estrogen-like effects. MCF-7 and SK-BR-3 cells were treated by solvent, 1–100 µM bisphenol-A (BPA), or 1–100 µM 4HR, respectively. 3-(4, 5-Dimethylthiazole-2-yl)- 2,5-diphenyltetrazolium bromide (MTT) assay and Western blot for extracellular signal-regulated kinase-1/-2 (ERK1/2), phosphorylated ERK1/2 (p-ERK1/2), estrogen receptor-α (ERα), and ERβ were done. As an in vivo study, ovariectomized rats (n = 15) received solvent, 125 mg/kg of 4HR, or 10 µg of 17-β estradiol via daily subcutaneous injection for 7 days. Blood samples were obtained for evaluation of prolactin levels. Pituitary glands and uteruses were biopsied for histological evaluation and Western blot analysis. Compared with the control group, the application of 4HR decreased the proliferation of MCF-7 and SK-BR-3 cells, while the application of BPA increased (p < 0.05). The application of BPA increased the expression of ERα, ERβ, and p-ERK1/2, but 4HR did not change the expression of ERα, ERβ, or p-ERK1/2 in MCF-7 cells. In an animal model, the 4HR group showed similar levels of ERα, ERβ, and prolactin expression in the pituitary gland compared to the solvent only group, while the estradiol group showed higher levels. Serum prolactin levels were similar between the 4HR and solvent only groups. Taken together, 1–100 µM 4HR did not show BPA-like behavior in MCF-7 cells, and 125 mg/kg of 4HR daily subcutaneous injection for 7 days did not demonstrate estradiol-like effects in ovariectomized rats. Collectively, 4HR has no estrogen-like effects on both ERα-positive cells and estrogen-deficient rat models.

show abstract

“…Melatonin is an antioxidant and preclinical and human studies document the links between melatonin and breast cancer [17,18]. In a lab study, melatonin inhibited the proliferation of estrogen receptor-positive breast cancer cells [19]. Coenzyme Q10 is a lipid-soluble antioxidant and the use of coenzyme Q10 was not beneficial for reducing cancer-related fatigue [20].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Dietary Supplements Use Between Receivers and Refusers of Adjuvant Breast Cancer Treatments

Standish¹,

Kim²,

Andersen³

2019

COR

View full text Add to dashboard Cite

The goal of this study was to compare dietary supplement use between women who received all recommended conventional breast cancer treatments (Receivers) with those who did not (Refusers). We sought to understand commonly used supplements, use frequency, and prescribers. Methods: A secondary analysis was conducted using baseline data of Breast Cancer Integrative Oncology Study, which recruited 369 women with breast cancer from integrative oncology clinics and Cancer Surveillance System registry in Western Washington State. Self-reported data and registry data were analyzed using descriptive statistics, t-tests, and X 2 tests to compare Receivers and Refusers in their demographic and disease characteristics and supplement use. Results: Refusers used more supplements than Receivers did after diagnosis, 5.43 ± 5.29 vs. 2.66 2.88, F = 26.32, p < 0.001. Refusers used more fish oil and garlic before diagnosis, and more green tea, vitamin C, melatonin, coenzyme Q10, turmeric, and garlic after the diagnosis than Receivers. Most Receivers and Refusers took supplements 5 or more days per week. Most of the supplements were self-prescribed except vitamin D and Melatonin, which were prescribed by medical doctors or CAM providers. Conclusions: Receivers and Refusers generally used the same top ten supplements, often antioxidants, although the frequency of use differed slightly, and Refusers took more supplements. Receivers, who are undergoing chemotherapy or radiotherapy need to know that taking antioxidants may influence treatment effectiveness. Refusers need to be informed that there is no strong evidence that the use of dietary supplements reduces recurrence or mortality.

show abstract

Melatonin inhibits the proliferation of breast cancer cells induced by bisphenol A via targeting estrogen receptor‐related pathways

Cited by 35 publications

References 34 publications

Ameliorative effects of melatonin against solid Ehrlich carcinoma progression in female mice

Ameliorative effects of melatonin against solid Ehrlich carcinoma progression in female mice

4-Hexylresorcinol Exhibits Different Characteristics to Estrogen

Comparison of Dietary Supplements Use Between Receivers and Refusers of Adjuvant Breast Cancer Treatments

Contact Info

Product

Resources

About